Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Lifted to Hold by Zacks Research

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday, Zacks reports.

AMRX has been the topic of several other reports. UBS Group reiterated a “buy” rating on shares of Amneal Pharmaceuticals in a report on Thursday, October 1st. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price target on the stock. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.25.

Amneal Pharmaceuticals Trading Up 2.0%

NASDAQ AMRX opened at $21.44 on Monday. The business’s 50-day moving average price is $18.93 and its two-hundred day moving average price is $15.62. Amneal Pharmaceuticals has a 12 month low of $9.99 and a 12 month high of $21.46.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.95 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director John Kiely sold 50,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the transaction, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. This trade represents a 19.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. The trade was a 85.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 413,016 shares of company stock valued at $7,216,567. Company insiders own 17.30% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AMRX. Allspring Global Investments Holdings LLC raised its holdings in Amneal Pharmaceuticals by 72.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after buying an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Amneal Pharmaceuticals during the second quarter valued at about $17,573,000. Principal Financial Group Inc. grew its holdings in shares of Amneal Pharmaceuticals by 527.9% during the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock valued at $12,089,000 after buying an additional 817,652 shares during the last quarter. Congress Asset Management Co. increased its position in shares of Amneal Pharmaceuticals by 94.7% during the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after acquiring an additional 741,577 shares in the last quarter. Finally, Quartz Partners LLC bought a new stake in shares of Amneal Pharmaceuticals during the first quarter worth about $5,559,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.